HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC anti-aging laser

This article was originally published in The Rose Sheet

Executive Summary

Palomar Medical Technologies is first company to receive FDA approval for a home-use laser device that treats periorbital wrinkles, the Burlington, Mass. company announces June 5. Developed by Palomar in conjunction with Johnson & Johnson Consumer Companies, the laser is based on years of research and "represents a major breakthrough in the aesthetic device industry," Palomar says. Noting laser treatment for the removal of wrinkles has been proven safe in doctor's offices for years, Palomar CEO Joseph P. Caruso stresses that FDA clearance allows consumers to use the product in their own home "for a fraction of the cost." Palomar is one of a number of companies exploring light-based cosmetic technologies; Home Skinovations recently introduced laser hair removal product Silk'n SensEpil (1"The Rose Sheet" March 30, 2009, p. 6)

You may also be interested in...



J&J announces Q3 results

Despite rosy outlook of many economists, Johnson & Johnson CFO and VP-Finance Dominic J. Caruso believes the recession continues to negatively impact U.S. consumer buying patterns and distributor inventory levels in the consumer products segment. During an Oct. 13 third-quarter call, the exec noted that the firm's "core strategy" for overcoming the slump is to "differentiate our products as well as focus on developing strong consumer brands." J&J's U.S. consumer business in the third quarter declined 4.4 percent to $1.69 billion, while the firm's international consumer product revenue was down 1.4 percent, at $2.3 billion; worldwide sales for the business slipped 2.7 percent to $4 billion. Its Aveeno and Dabao skin-care brands and Listerine mouthrinse performed well in Q3, firm notes. Separately, J&J has terminated its agreement with light-based cosmetic treatment developer Palomar Medical Technologies to develop and commercialize devices for reducing the signs of skin aging and reducing or preventing acne. Palomar intends to continue with the development of its home-use laser device to treat periorbital wrinkles, approved by FDA in June, and anticipates launching it in the second half of 2010 (1"The Rose Sheet" June 8, 2009)

Watch Out, Razors, Here Come Lasers; Skinovations’ Silk’n Rolling Out OTC

With the OTC launch of Home Skinovations' Silk'n SensEpil device this spring - and with TRIA Beauty expanding distribution of its system - conventional hair-removal products could begin losing favor with women seduced by the idea of laser hair removal in the home

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel